Abstract
Tau protein is critical for normal brain function but then it undergoes modification it is prone to aggregation into cytotoxic species which lead to diseases [1]. Hence, tau is a druggable target, as well as the biomarker of neurodegenerative disease. We reported on the detection of tau modification, specifically phosphorylation, and its inhibition by antibodies by using electrochemical impedance spectroscopy (EIS) [2]. In addition, the EIS was utilized to monitor binding interactions between large molecules, such as heparin, ferritin and transferrin to tau protein [3]. Tau protein biomarker detection was also achieved by using the same method. Currently, we are exploring tau protein self-assembly towards developing electrochemical assay for detection of early onset of tau pathology. Electrochemical assay for tau protein would allow for early detection and diagnosis of diseases, as well as drug inhibitor screening against neurodegenerations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
